Which Medicines Are Covered In Our Pharmacogenomic Test?

Pharmacogenomics in the UK: What's Covered?

If you’ve ever wondered why one antidepressant worked for a friend but not for you, or why some medications cause unpleasant side effects, pharmacogenomic (PGx) testing could hold the answer. By analysing your DNA, our test helps predict how your body is likely to respond to a wide range of medications — from common antidepressants like sertraline and citalopram, to treatments for pain, heart conditions, infections, and autoimmune disorders.

At AttoDiagnostics, we offer UK-based pharmacogenetic testing designed to support personalised prescribing. Whether you’re exploring options for psychiatric medications, managing a long-term condition, or just curious about your genetic response to certain drugs, this test gives patients and doctors powerful, science-based insights that help the individual and the system at large.

In this blog, we’ll outline all the medicines covered in our PGx panel — including which have strong clinical evidence, where genetic testing is strongly recommended, and which ones are critical to get right for safety. You’ll also find tables by specialty (e.g. mental health, cardiovascular, infection), helping you quickly understand what’s included and why it matters.

Understanding Different Evidence Levels

Pharmacogenomic evidence in this guide is drawn from internationally recognised sources including the Clinical Pharmacogenetics Implementation Consortium (CPIC), the U.S. Food and Drug Administration (FDA), the Dutch Pharmacogenetics Working Group (DPWG), and PharmGKB, a global pharmacogenomic database. Each medication is graded based on how strongly these bodies recommend PGx testing. CPIC A, FDA 1, or PharmGKB Level 1 is the most robust level of research. We have marked drugs in this category as “Critical PGx”, as the insights could have a huge impact on a patient’s life — potentially preventing serious adverse effects or treatment failure.

The next level is “Strongly recommend PGx”, where testing is highly supported by evidence — for example, CPIC B or FDA 2 — and may influence drug choice or dose, especially in complex cases or when safer alternatives are available.

Finally, we use “Recommend PGx” for drugs where early or moderate evidence suggests that genetics may play a role — such as FDA 3, CPIC C/D, or PharmGKB Level 2 or 3. In these cases, PGx testing can still provide useful insights but may be more supportive than decisive.

Pharmacogenomics for Analgesia: Personalising Pain Relief

Pain management is one of the clearest examples of how pharmacogenomics can improve safety and efficacy. Several commonly prescribed painkillers are influenced by your genetic makeup — particularly those that rely on enzymes like CYP2D6 for activation or breakdown. Our pharmacogenomic panel includes medications for both acute and chronic pain, from fast-acting surgical anaesthetics like alfentanil to widely used opioids such as codeine, tramadol, and hydrocodone.

Importantly, this is a highly actionable category, with critical PGx guidance in place for drugs like codeine, tramadol, and oliceridine, where getting the right dose (or avoiding the drug altogether) can be life-saving. Genetic variants can affect how quickly or slowly your body processes these medications — leading to either toxicity or lack of pain relief. For patients with complex pain needs or concerns about opioid side effects, PGx insights offer an evidence-based way to tailor treatment safely.

Drug	Typical Use (Analgesia)	PGx Evidence	Medical Association
Alfentanil	Rapid pain relief during surgical procedures	Recommend PGx	PharmGBK 3
Carisoprodol	Muscle pain relief via central sedation	Recommend PGx	FDA 3
Codeine	Mild-to-moderate pain and cough relief	Critical PGx	CPIC A, FDA 1
Fentanyl	Severe pain, often in surgical or cancer settings	Recommend PGx	PharmGBK 3
Hydrocodone	Moderate pain and cough suppressant use	Strongly recommend PGx	CPIC B
Morphine	Severe acute or chronic pain management	Recommend PGx	PharmGBK 3
Oliceridine	Acute moderate-to-severe pain, hospital use	Critical PGx	FDA 1
Tramadol	Moderate pain with lower opioid potency	Critical PGx	CPIC A, FDA 1

Pharmacogenomics for Cardiovascular Care: Personalising Heart Medication Prescribing

Cardiovascular disease remains one of the leading causes of death worldwide — and yet many of its treatments are impacted by how individuals metabolise medications. Pharmacogenomic testing provides essential insights into how patients respond to key drug classes such as statins, anticoagulants, beta-blockers, and antiarrhythmics.

This is one of the most robust and clinically actionable categories in our panel, with several medications falling under the “critical PGx” tier. For example, warfarin, clopidogrel, and simvastatin are well-established in PGx guidelines, where genetic variation can dramatically affect safety or efficacy. Additionally, our test covers statins like rosuvastatin, fluvastatin, and pravastatin, where variants in genes like SLCO1B1 can increase the risk of statin-induced myopathy.

Patients with hypertension, high cholesterol, or arrhythmias may benefit significantly from PGx-guided prescribing — reducing the trial-and-error approach and helping to avoid adverse events. Whether you’re on a preventative statin or managing atrial fibrillation with anticoagulants, genetic testing is increasingly viewed as essential for safe and effective treatment in cardiovascular care.

Drug	Typical Use (Cardiovascular)	PGx Evidence	Medical Association
Atorvastatin	Lowers cholesterol to reduce cardiovascular risk	Strongly recommend PGx	CPIC B, FDA 3
Carvedilol	Beta-blocker for heart failure and hypertension	Strongly recommend PGx	FDA 2
Clopidogrel	Prevents clotting after stroke or heart attack	Critical PGx	CPIC A, FDA 1
Flecainide	Treats abnormal heart rhythms (arrhythmias)	Critical PGx	DPWG
Fluvastatin	Reduces LDL cholesterol, lowers atherosclerosis risk	Critical PGx	CPIC A
Lovastatin	Manages high cholesterol, prevents cardiovascular events	Critical PGx	CPIC A
Mavacamten	Treats obstructive hypertrophic cardiomyopathy	Strongly recommend PGx	FDA 2
Metoprolol	Controls heart rate and blood pressure	Strongly recommend PGx	CPIC B
Nebivolol	Beta-blocker, improves endothelial function and lowers BP	Recommend PGx	FDA 3
Pitavastatin	Statin for cholesterol reduction, fewer drug interactions	Critical PGx	CPIC A
Pravastatin	Cholesterol-lowering, lower risk of heart attack or stroke	Critical PGx	CPIC A
Propafenone	Rhythm control for atrial fibrillation or tachycardia	Critical PGx	DPWG, FDA 1
Rosuvastatin	Potent statin, lowers LDL and stabilizes plaques	Critical PGx	CPIC A
Simvastatin	Reduces cholesterol, used in CVD prevention	Critical PGx	CPIC A, FDA 2
Warfarin	Anticoagulant for stroke prevention in atrial fibrillation	Critical PGx	CPIC A, FDA 1

 

Pharmacogenomics for Contraceptive and Hormonal Therapies: Personalising Female Health Treatment

Hormonal medications play a vital role in managing reproductive health, yet their effectiveness and safety can vary widely between individuals. Our pharmacogenomic test includes select drugs in this space, helping to guide decisions around birth control, hormone-related mood disorders, and conditions like endometriosis.

While this category is still emerging in terms of formal guideline coverage, it includes notable entries. Flibanserin, used for hypoactive sexual desire disorder, is a critical PGx medication, with FDA-level guidance due to the increased risk of side effects in poor metabolisers. Oral contraceptives, though not yet widely covered in clinical PGx guidelines, are associated with genetic variants that may influence risk of blood clots — a consideration for some women with family history or thrombophilia.

Elagolix, a non-hormonal treatment for endometriosis, is also included, with FDA-acknowledged gene–drug interaction data that can inform monitoring. While not as developed as categories like oncology or cardiovascular care, PGx in this field holds meaningful potential for women seeking more tailored and safer hormonal therapies.

Drug	Typical Use (Contraceptive and HRT)	PGx Evidence	Medical Association
Elagolix	Treats endometriosis and fibroids	Recommend PGx	FDA 3
Flibanserin	Treats low sexual desire disorder in women	Critical PGx	FDA 1
Oral Contraceptives	Birth control and hormonal regulation	Recommend PGx	PharmGKB 2B

 

Pharmacogenomics for Endocrinology: Personalising Diabetes Management

In endocrinology, pharmacogenomics is beginning to shape more precise approaches to common conditions like type 2 diabetes. While this category currently includes fewer medications, it contains high-impact drugs where genetic differences can meaningfully alter outcomes.

Nateglinide, an oral diabetes medication that stimulates insulin release, is one such example. With critical PGx status, it’s influenced by variations in genes that affect drug metabolism, impacting both efficacy and the risk of side effects. For patients managing blood sugar levels, PGx testing offers an opportunity to fine-tune therapy for better control and safety.

Drug	Typical Use (Endocrinology)	PGx Evidence	Medical Association
Nateglinide	Stimulates insulin release in type 2 diabetes	Critical PGx	FDA 1

 

Pharmacogenomics for Gastroenterology: Personalising Gut and Anti-Nausea Treatments

The gastrointestinal system is closely tied to how medications are absorbed, processed, and tolerated — making pharmacogenomics a valuable tool in this area. Our PGx panel includes a wide range of proton pump inhibitors (PPIs) and antiemetics, many of which show clear evidence of gene–drug interactions.

Medications like omeprazole, lansoprazole, and pantoprazole are influenced by variations in CYP2C19, a gene that affects how these drugs are metabolised. For patients with GERD or ulcers, this can mean the difference between effective acid suppression and treatment failure. These drugs carry critical or strongly recommended PGx status, depending on the strength of the supporting evidence.

Also featured are anti-nausea medications like ondansetron, meclizine, and metoclopramide, which can cause serious side effects in patients with certain genetic variants. In this category, PGx testing not only improves therapeutic success — it can help avoid complications like drug-induced movement disorders or poor treatment response, especially in cancer or surgical settings.

Drug	Typical Use (Gastroenterology)	PGx Evidence	Medical Association
Dexlansoprazole	Acid suppression (PPI for GERD)	Strongly recommend PGx	CPIC B, FDA 3
Dronabinol	Appetite stimulant, antiemetic	Critical PGx	FDA 1
Esomeprazole	Acid suppression (PPI for ulcers, reflux)	Recommend PGx	FDA 3
Lansoprazole	Acid suppression (PPI for GERD)	Critical PGx	CPIC A, FDA 3
Meclizine	Anti-nausea, vertigo	Critical PGx	FDA 1
Metoclopramide	GI motility disorders, nausea	Critical PGx	FDA 1
Omeprazole	Acid suppression (PPI for GERD)	Critical PGx	CPIC A, FDA 3
Ondansetron	Antiemetic (nausea from chemo, surgery)	Critical PGx	CPIC A
Pantoprazole	Acid suppression (PPI for GERD)	Critical PGx	CPIC A, FDA 31
Rabeprazole	Acid suppression (PPI for ulcers, reflux)	Recommend PGx	FDA 3

 

Pharmacogenomics for Infection: Personalising Antifungal Treatment

While PGx guidance in infectious disease is still developing, certain high-risk medications already have strong genetic associations. Voriconazole, a powerful antifungal used for serious infections like aspergillosis, carries critical PGx status. Variants in the CYP2C19 gene can significantly alter drug levels, impacting both treatment effectiveness and the risk of toxicity — making PGx testing especially valuable in immunocompromised or critically ill patients.

Drug	Typical Use (Infection)	PGx Evidence	Medical Association
Voriconazole	Antifungal for serious infections (e.g., aspergillosis)	Critical PGx	CPIC A, FDA 2

 

Pharmacogenomics for Mental Health & ADHD: Personalising Psychiatric and Neurological Treatment

Mental health is one of the most established and clinically impactful areas for pharmacogenomics. Many antidepressants, antipsychotics, and ADHD medications are metabolised by genes like CYP2D6, CYP2C19, and others that significantly influence how individuals respond to treatment. Our PGx panel includes over 35 mental health–related medications, with a large proportion receiving critical or strongly recommended PGx status.

From commonly prescribed SSRIs like sertraline, citalopram, and paroxetine, to tricyclic antidepressants such as amitriptyline and nortriptyline, genetic testing helps reduce the risk of side effects like sedation or cardiac effects, and increases the likelihood of therapeutic benefit. It also informs treatment decisions for complex conditions like schizophrenia, bipolar disorder, and ADHD, where agents like aripiprazole, risperidone, and atomoxetine are often used.

Whether you're starting your first antidepressant or managing a complex psychiatric regimen, this category offers some of the strongest evidence for clinical action, helping practitioners and patients alike find a safer, more effective path forward.

Drug	Typical Use (Mental Health & ADHD)	PGx Evidence	Medical Association
Amitriptyline	Tricyclic antidepressant, also for pain	Critical PGx	CPIC A, FDA 3
Amoxapine	Tricyclic antidepressant	Recommend PGx	FDA 3
Amphetamine	ADHD treatment	Critical PGx	FDA 1
Aripiprazole	Antipsychotic for schizophrenia, bipolar	Critical PGx	FDA 1
Aripiprazole lauroxil	Long-acting antipsychotic injection	Critical PGx	FDA 1
Atomoxetine	Non-stimulant ADHD medication	Critical PGx	CPIC A, FDA 1
Brexpiprazole	Antipsychotic for depression, schizophrenia	Critical PGx	FDA 1
Bupropion	Antidepressant and smoking cessation aid	Recommend PGx	PharmGKB 3
Citalopram	SSRI for depression and anxiety	Critical PGx	CPIC A, FDA 1
Clomipramine	Tricyclic antidepressant (OCD focus)	Strongly recommend PGx	CPIC B, FDA 3
Clozapine	Antipsychotic for schizophrenia	Critical PGx	FDA 1
Desipramine	Tricyclic antidepressant	Strongly recommend PGx	CPIC B, FDA 3
Diazepam	Anxiety, muscle relaxant, anticonvulsant	Recommend PGx	FDA 3
Doxepin	Tricyclic antidepressant	Strongly recommend PGx	CPIC B, FDA 3
Escitalopram	SSRI for depression/anxiety	Critical PGx	CPIC A, FDA 3
Fluoxetine	SSRI for depression/anxiety	Recommend PGx	Product Monograph (Actionable)
Fluvoxamine	SSRI for OCD/depression	Strongly recommend PGx	CPIC B, FDA 3
Haloperidol	Antipsychotic	Critical PGx	DPWG
Iloperidone	Antipsychotic for schizophrenia	Critical PGx	FDA 1
Imipramine	Tricyclic antidepressant	Strongly recommend PGx	CPIC B, FDA 3
Lofexidine	Alpha-2 agonist for opioid withdrawal	Critical PGx	FDA 1
Methylphenidate	Stimulant for ADHD	Recommend PGx	PharmGKB 4
Nicotine Replacement	Smoking cessation aid	Recommend PGx	PharmGKB 3
Nortriptyline	Tricyclic antidepressant	Critical PGx	CPIC A, FDA 3
Olanzapine	Antipsychotic	Recommend PGx	PharmGKB 3
Paroxetine	SSRI for depression	Critical PGx	CPIC A, FDA 3
Perphenazine	Antipsychotic	Strongly recommend PGx	FDA 2
Pimozide	Antipsychotic for Tourette’s	Critical PGx	FDA 1
Protriptyline	Tricyclic antidepressant	Recommend PGx	FDA 3
Quetiapine	Antipsychotic	Critical PGx	DPWG
Risperidone	Antipsychotic	Critical PGx	DPWG, FDA 3, PharmGKB 3
Sertraline	SSRI for depression/anxiety	Critical PGx	CPIC A
Thioridazine	Antipsychotic	Critical PGx	FDA 1
Trimipramine	Tricyclic antidepressant	Strongly recommend PGx	CPIC B, FDA 3
Venlafaxine	SNRI for depression/anxiety	Critical PGx	CPIC B, FDA 1
Viloxazine	Non-stimulant for ADHD	Recommend PGx	FDA 3
Vortioxetine	Antidepressant	Critical PGx	CPIC A, FDA 1
Zuclopenthixol	Antipsychotic	Critical PGx	DPWG

 

Pharmacogenomics for Neurology: Personalising Treatment for Seizures, Memory, and Movement Disorders

In neurology, pharmacogenomics is becoming increasingly valuable in guiding safe and effective treatment for conditions like epilepsy, Alzheimer’s disease, and movement disorders such as tardive dyskinesia or Huntington’s disease. Several drugs in this category carry critical PGx designations, particularly where metabolism by CYP2C19, CYP2D6, or transport genes can affect drug levels, toxicity, or therapeutic response.

Anticonvulsants like phenytoin, fosphenytoin, clobazam, and brivaracetam feature prominently, with PGx testing helping to reduce risks such as severe skin reactions or sedation. Likewise, treatments for neurological symptoms — including valbenazine, deutetrabenazine, and tetrabenazine — benefit from genetic guidance to optimise dosing and avoid adverse effects, especially in psychiatric–neurologic crossover patients.

Even medications used for migraine or cognitive symptoms (such as donepezil or propranolol) are represented, making PGx testing a meaningful addition to neurological care. For clinicians working in neuropsychiatry, geriatric medicine, or movement disorders, pharmacogenomics offers a valuable tool for safer prescribing and better patient outcomes.

Drug	Typical Use (Neurology)	PGx Evidence	Medical Association
Brivaracetam	Anticonvulsant for epilepsy	Critical PGx	FDA 1
Clobazam	Benzodiazepine for seizures and epilepsy	Critical PGx	FDA 1
Deutetrabenazine	Treats chorea in Huntington's, tardive dyskinesia	Critical PGx	FDA 1
Donepezil	Cognitive enhancer for Alzheimer’s disease	Recommend PGx	FDA 3
Fosphenytoin	Anticonvulsant	Critical PGx	CPIC A, FDA 1
Galantamine	Cognitive enhancer for Alzheimer’s disease	Recommend PGx	FDA 3
Phenytoin	Anticonvulsant	Critical PGx	CPIC A, FDA 1
Pitolisant	Narcolepsy, sleep disorders	Critical PGx	FDA 1
Propranolol	Migraine, essential tremor, anxiety	Recommend PGx	FDA 3
Tetrabenazine	Treats chorea in Huntington’s disease	Critical PGx	FDA 1
Valbenazine	Tardive dyskinesia	Critical PGx	FDA 1

 

Pharmacogenomics for Oncology: Personalising Cancer Therapy

Oncology is one of the most mature and clinically validated areas of pharmacogenomics. Many cancer therapies have narrow therapeutic windows or severe toxicity risks, and genetic variation can dramatically alter both efficacy and safety. That’s why several medications in this category carry critical PGx status — with strong guidance from the FDA and CPIC for dose adjustments or alternative therapies.

Our PGx panel includes high-impact drugs like capecitabine and fluorouracil, where deficiencies in DPYD can lead to life-threatening toxicity. Also included are targeted therapies like gefitinib and tamoxifen, where drug metabolism and response are influenced by genes such as CYP2D6 and EGFR. In many cases, PGx insights aren’t just helpful — they’re standard of care.

For patients undergoing chemotherapy or targeted treatments, pharmacogenomic testing supports safer dosing and better outcomes. In this category, genetic testing can truly be the difference between success and serious complication — making it an essential component of precision oncology.

Drug	Typical Use (Oncology)	PGx Evidence	Medical Association
Capecitabine	Antimetabolite for breast and colorectal cancer	Critical PGx	CPIC A, FDA 1
Erdafitinib	FGFR inhibitor for bladder cancer	Critical PGx	FDA 1
Fluorouracil	Antimetabolite for colorectal and breast cancer	Critical PGx	CPIC A, FDA 1
Gefitinib	EGFR inhibitor for non-small cell lung cancer	Critical PGx	FDA 1
Tamoxifen	SERM for hormone receptor-positive breast cancer	Critical PGx	CPIC A, FDA 3

 

Pharmacogenomics for Rheumatology & Autoimmune Care: Personalising Anti-Inflammatory and Immunosuppressant Treatment

In rheumatology and autoimmune care, patients are often prescribed long-term treatments with significant risks — from immunosuppressants to NSAIDs. Our pharmacogenomic panel includes a range of these medications, several of which carry critical or strongly recommended PGx status due to risks like severe toxicity or reduced efficacy.

Standout examples include azathioprine, mercaptopurine, and thioguanine, where genetic variation in TPMT and NUDT15 enzymes can lead to life-threatening bone marrow suppression. Likewise, medications like methotrexate and NSAIDs such as meloxicam and piroxicam may be influenced by genetic differences in metabolism or transport, particularly affecting safety profiles.

For clinicians managing chronic autoimmune conditions — from rheumatoid arthritis to Crohn’s disease — PGx testing can inform safer, more personalised long-term therapy.

Drug	Typical Use	PGx Evidence	Medical Association
Azathioprine	Autoimmune diseases, transplant immunosuppression	Critical PGx	CPIC A, FDA 1
Celecoxib	NSAID for arthritis and pain	Critical PGx	CPIC A, FDA 1
Cevimeline	Treats dry mouth in Sjögren’s syndrome	Strongly recommend PGx	FDA 2
Cyclosporine	Immunosuppressant for autoimmune and transplant use	Recommend PGx	PharmGKB 3
Flurbiprofen	NSAID for arthritis, pain relief	Critical PGx	CPIC A, FDA 1
Ibuprofen	NSAID for pain, inflammation	Critical PGx	CPIC A, FDA 3
Meloxicam	NSAID for arthritis	Critical PGx	CPIC A, FDA 1
Mercaptopurine	Leukemia, autoimmune diseases	Critical PGx	CPIC A, FDA 1
Methotrexate	Autoimmune diseases, chemotherapy	Strongly recommend PGx	PharmGKB 2A
Piroxicam	NSAID for arthritis	Critical PGx	CPIC A, FDA 1
Siponimod	Multiple sclerosis	Critical PGx	FDA 1
Tacrolimus	Transplant and autoimmune immunosuppression	Critical PGx	CPIC A, FDA 1
Tenoxicam	NSAID for arthritis	Critical PGx	CPIC A
Thioguanine	Leukemia, inflammatory bowel disease	Critical PGx	CPIC A, FDA 1

 

Pharmacogenomics for Urology: Personalising Bladder and Prostate Treatment

Although pharmacogenomic research in urology is still emerging, several medications used for overactive bladder and benign prostatic hyperplasia (BPH) show meaningful gene–drug interactions. Our test includes drugs like tolterodine, mirabegron, and tamsulosin, many of which rely on CYP2D6 or CYP3A4 metabolism.

Most medications in this group carry a “recommend PGx” status, highlighting opportunities to improve dosing precision or avoid side effects such as dry mouth, dizziness, or elevated blood pressure. As the evidence base grows, PGx will increasingly support personalisation in urological treatment — especially for patients managing complex or multi-drug regimens.

Drug	Typical Use (Urology)	PGx Evidence	Medical Association
Darifenacin	Overactive bladder	Recommend PGx	FDA 3
Fesoterodine	Urinary incontinence, overactive bladder	Recommend PGx	FDA 3
Mirabegron	Overactive bladder	Recommend PGx	FDA 3
Tamsulosin	Benign prostatic hyperplasia (BPH)	Recommend PGx	FDA 3
Tolterodine	Overactive bladder	Strongly recommend PGx	FDA 2

 

Pharmacogenomics for Other Conditions: Personalising a Range of Targeted Therapies

Our panel also includes a set of important medications that don’t fall neatly into one clinical category but have strong pharmacogenomic relevance. These include drugs like efavirenz (used in HIV), eliglustat (for Gaucher disease), and salmeterol (a respiratory medication), alongside thrombopoietin receptor agonists such as eltrombopag and avatrombopag.

Some of these, such as abrocitinib and efavirenz, are listed with critical PGx status, where dosage or treatment decisions are guided directly by genotype. This section reflects the growing influence of PGx across modern medicine — even in niche or highly specialised therapies — and highlights the value of broad pharmacogenomic screening in supporting better prescribing.

Drug	Typical Use	PGx Evidence	Medical Association
Abrocitinib	JAK1 inhibitor for atopic dermatitis	Critical PGx	FDA 1
Avatrombopag	Thrombocytopenia in chronic liver disease	Recommend PGx	FDA 3
Efavirenz	Antiretroviral (HIV)	Strongly recommend PGx	CPIC A, FDA 2
Eliglustat	Gaucher disease type 1	Critical PGx	FDA 1
Eltrombopag	Chronic immune thrombocytopenia	Recommend PGx	TBC
Lusutrombopag	Thrombocytopenia in chronic liver disease	Recommend PGx	TBC
Salmeterol	Long-acting beta agonist for asthma/COPD	Strongly recommend PGx	PharmGKB 2A

 

Conclusion: Accessible Pharmacogenomic Testing in the UK

Pharmacogenomic testing is changing the way medicines are prescribed — moving us away from trial-and-error toward safer, more effective, personalised care. Whether you're navigating mental health treatment, managing a long-term condition, or exploring options for cancer therapy or pain relief, our panel includes a wide range of medications supported by strong, evidence-based PGx guidance.

At AttoDiagnostics, we provide UK-based pharmacogenetic testing that’s easy to access, clinically validated, and designed to support both patients and healthcare professionals. If you're wondering whether pharmacogenomic testing is available through the NHS or want to know where to get tested privately, we’re here to help you find the right path.

To find out more or book a consultation, visit our website — and take the first step toward personalised prescribing, powered by your DNA.

Request a PGx Demo